Close Menu

NEW YORK – Organ transplant diagnostics company CareDx announced today that it has formed a strategic partnership with NanoString Technologies to develop HistoMap, a gene expression profiling test to identify allograft rejection in transplant biopsy tissue.

Under the terms of the agreement, CareDx will combine its expertise and transplant registries with NanoString's nCounter platform, and its newly introduced Human Organ Transplant panel — a 770-gene panel designed to evaluate human immune response following organ transplantation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.